How WONDERBIOTICS Supports GLP-1 Related Wellness Goals

GLP-1 has become one of the most discussed topics in metabolic health. The rise of GLP-1 receptor agonist medications has drawn attention to how this hormone influences appetite, blood sugar regulation, and body weight. Alongside prescription medications, many people are looking for non-pharmaceutical approaches that work through similar biological pathways.

WONDERBIOTICS includes ingredients studied for their effects on GLP-1 support and appetite-related biology, offering a complementary approach for people navigating food noise, cravings, and metabolic wellness.

This article covers what the research says about GLP-1 support through non-medication pathways, how specific ingredients in the WONDERBIOTICS formula connect to that evidence, and what to realistically expect from a probiotic-based approach.

What GLP-1 Does and Why It Matters for Appetite

GLP-1, or glucagon-like peptide-1, is an incretin hormone produced primarily by L-cells in the small intestine and colon. It is released in response to food intake and exerts several effects relevant to metabolic health. GLP-1 slows gastric emptying, reduces appetite signals in the brain, and stimulates glucose-dependent insulin secretion from the pancreas.¹

These effects are the basis for GLP-1 receptor agonist medications, which are used for type 2 diabetes management and weight loss. The medications work by activating the same receptor that natural GLP-1 acts on, but at higher and more sustained levels than the body produces on its own.

Natural GLP-1 has a short half-life of approximately 2 minutes because it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4).² This means the body's own GLP-1 is constantly produced and broken down in a rapid cycle. Strategies that increase endogenous GLP-1 production or slow its degradation are of interest for metabolic support outside of pharmaceutical interventions.

The gut microbiome plays a role in this process. Certain gut bacteria produce short-chain fatty acids such as butyrate and propionate through fiber fermentation, and these metabolites have been shown to stimulate GLP-1 secretion from intestinal L-cells.³ This is one pathway through which the gut microbiome and GLP-1 biology intersect.

Terms to Know

• Incretin effect: the phenomenon where oral glucose intake stimulates a greater insulin response than an equivalent intravenous glucose load, mediated by gut hormones including GLP-1.
• DPP-4: an enzyme that rapidly degrades active GLP-1 in the bloodstream, limiting its half-life to approximately 2 minutes and making endogenous GLP-1 a short-acting signal.

Eriomin and GLP-1 Support in the WONDERBIOTICS Formula

One of the key ingredients in WONDERBIOTICS relevant to GLP-1 is Eriomin, a standardized citrus flavonoid complex primarily composed of luteolin. Eriomin has been studied for its effects on GLP-1 production and metabolic markers in human clinical trials.

In a randomized controlled trial published in the Journal of Nutritional Biochemistry, Eriomin supplementation was associated with increased active GLP-1 levels and improvements in oxidative stress and inflammatory markers in adults with prediabetes.⁴ The proposed mechanism involves inhibition of DPP-4, the enzyme that degrades GLP-1, allowing endogenous GLP-1 to remain active for longer periods.

This positions Eriomin as an ingredient studied for GLP-1 support through an endogenous pathway. Rather than introducing an external GLP-1 agonist, Eriomin works by modulating the body's natural GLP-1 production and degradation cycle. The trial was conducted in a prediabetic adult population, and the findings should be understood within that context. The results do not imply that Eriomin is equivalent to GLP-1 medications, and no direct comparison between Eriomin and prescription GLP-1 agonists has been conducted.

In the WONDERBIOTICS formula, Eriomin is positioned specifically for GLP-1 support. This is a distinct role from other ingredients in the formula, such as B420, which is positioned for body fat management based on a separate line of evidence.

Food Noise, Cravings, and the GLP-1 Connection

Food noise refers to the persistent, intrusive thoughts about food that many people experience throughout the day. This can include thinking about the next meal before finishing the current one, feeling unable to stop thinking about certain foods, or experiencing cravings that are difficult to manage through willpower alone. People taking GLP-1 medications frequently report a dramatic reduction in food noise, which has drawn attention to the role of GLP-1 signaling in appetite regulation.⁵

The mechanism through which GLP-1 reduces food noise is thought to involve both central and peripheral pathways. GLP-1 receptors are present in brain regions involved in reward and motivation, including the mesolimbic system. Activation of these receptors may reduce the reward value of food cues and decrease the salience of food-related thoughts.⁶ Peripheral effects, including slowed gastric emptying and gut-brain signaling through the vagus nerve, may also contribute to reduced appetite drive.

For people not taking GLP-1 medications but experiencing food noise and cravings, the question is whether supporting endogenous GLP-1 through non-pharmaceutical ingredients can produce a meaningful reduction in these experiences. The research on this specific question is limited. The Eriomin trial demonstrated increased GLP-1 levels and improved metabolic markers, but it did not specifically measure food noise or craving intensity as outcomes.

The logical connection is that if food noise is partly mediated by GLP-1 signaling, and if an ingredient increases active GLP-1 levels, then it may have some effect on the appetite-related experiences that GLP-1 medications are known to reduce. This is a reasonable hypothesis based on the pharmacology, but it has not been directly tested in a clinical trial with food noise as the primary endpoint.

How WONDERBIOTICS Approaches This Space

WONDERBIOTICS is formulated to address metabolic health through multiple pathways, with ingredients positioned for specific functions rather than as a general-purpose blend.

The formula includes Eriomin for GLP-1 support, backed by a randomized controlled trial showing increased active GLP-1 levels.⁴ It includes B420 for body fat management, backed by a 6-month randomized controlled trial showing reductions in body fat mass in overweight adults.⁷ It uses PolarSeal Technology for delivery protection, which in testing showed 99.9% strain survival in gut-like acidic conditions and 98.2% bacterial viability through the point of consumption. These are test results and consumption-pre data, not in-vivo measurements.

The core ingredients are backed by 624 clinical studies involving 44,692 participants. This is ingredient-level evidence, not finished-product data, and the studies were conducted on the specific strains and compounds used in the formula rather than on the product as a whole.

For people exploring GLP-1 support outside of medication, the relevant question is whether the ingredients in WONDERBIOTICS connect to the biological pathways involved in GLP-1 signaling and appetite regulation. The evidence for Eriomin on GLP-1 is direct, having been measured in a human clinical trial.⁴ The evidence for B420 on body fat is also direct, though from a general overweight adult population rather than GLP-1 medication users specifically.⁷

The formula does not claim to replicate the effects of GLP-1 medications. The magnitude of GLP-1 increase from Eriomin is modest compared to pharmaceutical agonists, and the research on food noise reduction through endogenous GLP-1 modulation is still in early stages. What the formula does offer is a collection of ingredients, each with published evidence for a specific metabolic function, designed to work through natural pathways rather than pharmaceutical intervention.

For those seeking to understand the broader context of probiotics and GLP-1 related health, or exploring how gut microbiome interventions may complement metabolic wellness goals, the WONDERBIOTICS formula provides an evidence-grounded starting point.

This article is for educational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. GLP-1 medications should only be used under the guidance of a licensed healthcare provider. If you are taking GLP-1 medications or managing a metabolic condition, talk with your clinician before starting any supplement.

References

1. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(06)00079-4
2. Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol. 2020;11:388. https://www.frontiersin.org/articles/10.3389/fendo.2020.00388/full
3. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015;11(10):577-591. https://www.nature.com/articles/nrendo.2015.128
4. Luzardo-Olimpi L, Silva-Beltrán NP, Gardea-Béjar AA, et al. Eriomin luteolin-based citrus flavonoid exhibits antidiabetic activity via GLP-1 secretion and modulation of mitochondrial function. J Nutr Biochem. 2024;124:109537. https://www.sciencedirect.com/science/article/pii/S0955286323002590
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
6. Trapp S, Brierley DI. Brain GLP-1 and the regulation of food intake: GLP-1 action in the brainstem and hypothalamus. J Endocrinol. 2022;253(1):R1-R18. https://joe.bioscientifica.com/view/journals/joe/253/1/JOE-21-0249.xml
7. Stenman LK, Edlund A, Burcelin R, et al. Probiotic B420 and L. gasseri BNR17 improve body fat mass and insulin sensitivity in overweight adults. Nutrients. 2020;12(11):3476. https://www.mdpi.com/2072-6643/12/11/3476